Compare AstraZeneca plc (AZN) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs MobilEye Global Inc — how do they compare? AstraZeneca plc trades at $158.62 (market cap $248.14B), while MobilEye Global Inc trades at $8.82 (market cap $7.54B). The key difference: AstraZeneca plc is far larger — about 32.9× MobilEye Global Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| AZN | MBLY | |
|---|---|---|
Market Cap | $248.14B | $7.54B |
Sector | Health | Technology |
52-Week High | $209.48 | $15.54 |
52-Week Low | $147.06 | $6.56 |
Enterprise Value | $275.41B | $6.10B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Mobileye Global Inc. (MBLY) trades at $8.77, up 0.23% on the day, with a bullish technical signal driven by moving averages. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $0.19 surpassing expectations, but faces fundamental challenges with a net income margin of -201.49% in 2026. Recent news highlights CEO transition and expanded partnerships, such as the Stellantis ADAS supply deal announced July 21, 2026.
The outlook is mixed: analyst consensus is bullish with a $11.40 price target (61.54% buy ratings), but high valuation (EV/EBITDA 43.25) and profitability risks persist. Investment opportunity lies in autonomous driving growth, while key risks include leadership uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
